

VPA10454/038/001

**Eurican DAP lyophilisate and solvent for suspension for injection**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - B35 a)	VNRA - Vet - B35 a) - a) Tightening of specification limits - B35 a) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — tightening of specification limits	16/02/24
Vet - G.I.4	VRA-S - Vet - G.I.4 - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data. - G.I.4 Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data.	16/02/24
Vet - F.II.e.5 z)	VRA-S - Vet - F.II.e.5 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.5 z) Quality Changes - Container closure system -Change in pack size of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	16/02/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	16/02/24
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	06/11/23
Vet - F.I.d.1 c)	VRA-S - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test period/storage period supported by real time data - F.I.d.1 c) Quality Changes - Active Substance - Stability -Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data	30/08/23

Vet - F.II.b.3 z)	VRA-S - Vet - F.II.b.3 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.3 z) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	24/03/23
Vet - F.I.a.1 d)	VRA-S - Vet - F.I.a.1 d) - d) The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - F.I.a.1 d) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product	16/12/22
B.I.a.2.z	IB - B.I.a.2.z - z Other variation - B.I.a.2.z - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - Minor change to the restricted part of an Active Substance Master File	29/03/22
B.I.b.2.d	II - B.I.b.2.d - d) Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - B.I.b.2.d - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance	29/03/22